This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
BD Merges Biosciences & Diagnostics Business With Waters
by Zacks Equity Research
BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play MedTech focus.
BDXPositive Net Change CAHPositive Net Change COOPositive Net Change VCYTNegative Net Change
medical medical-devices
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
by Indrajit Bandyopadhyay
ISRG has lost 13% in three months, but strong da Vinci 5 adoption and rising procedures raise a bigger question: is this pullback a buying opportunity?
JNJPositive Net Change MDTNegative Net Change SYKPositive Net Change ISRGPositive Net Change
medical medical-devices
HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?
by Debanjana Dey
Hims & Hers expands into new specialties and proactive testing while revenue and subscribers grow. However, regulatory, legal and margin pressures raise concerns.
TDOCNegative Net Change HIMSNegative Net Change TEMNegative Net Change
medical medical-devices
Medical Device Stocks to Report Earnings on Feb. 12: BAX, WST & DXCM
by Indrajit Bandyopadhyay
BAX, WST & DXCM gear up for Q4 earnings amid macro pressure, steady revenue growth and AI-driven demand.
BAXPositive Net Change DXCMNegative Net Change WSTPositive Net Change
medical medical-devices
3 Stocks With Upgraded Broker Ratings to Buy Amid AI-Related Headwinds
by Swayta Shah
Broker upgrades make J, NVST and TPR top picks amid an AI-driven sell-off as markets demand clearer AI monetization and disciplined spending.
TPRPositive Net Change NVSTPositive Net Change JNegative Net Change
construction medical medical-devices retail
EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs
by Zacks Equity Research
Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.
ISRGPositive Net Change ALGNPositive Net Change EWPositive Net Change NVSTPositive Net Change
earnings medical medical-devices
Baxter to Post Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
BAX's fourth-quarter results are likely to reflect muted revenue growth and an EPS decline due to ongoing infusion therapy and IV fluid headwinds.
BAXPositive Net Change MASIPositive Net Change DXCMNegative Net Change MMSINegative Net Change
medical medical-devices
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD's growth rests on AirSeal, Buffalo Filter and BioBrace as supply chains normalize, even as tariffs and a GI exit pressure EPS.
CNMDNegative Net Change ISRGPositive Net Change ALGNPositive Net Change CAHPositive Net Change
medical medical-devices
ECL Stock Falls in Pre-Market Despite Q4 Earnings Beat, Margins Expand
by Zacks Equity Research
Ecolab posts strong Q4 earnings with margin expansion and solid segment growth, but cautious sentiment persists despite gains in water, pest and life sciences.
ECLPositive Net Change DVAPositive Net Change CAHPositive Net Change DOCSNegative Net Change
earnings medical medical-devices
GEHC Launches ReadyFix Fleet Management to Boost ECG Efficiency
by Zacks Equity Research
GE HealthCare launches ReadyFix in the United States, a remote fleet management tool for MAC VU360 ECGs to boost device uptime and efficiency across hospitals.
ISRGPositive Net Change ATRCNegative Net Change VCYTNegative Net Change GEHCNegative Net Change
medical medical-devices